InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,795.60
(
0.60%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
-0.63%
)
Bitcoin
57,884.96
(
0.93%
)
Post# of 27676
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

tibt913

Send PM Follow Ignore
Followers 13
Posts 577
Boards Moderated 0
Alias Born 01/23/2014

tibt913

Re: None

Sunday, 07/16/2017 10:22:11 AM

Sunday, July 16, 2017 10:22:11 AM

Post# of 27676
http://adisinsight.springer.com/drugs/800037733
Latest Information Update: 14 Jun 2017
At a glance
Originator Rutgers; Zhengzhou University
Developer Biosuccess Biotech; Rich Pharmaceuticals; Rutgers
Class Antineoplastics; Antiretrovirals; Esters; Small molecules
Mechanism of Action Apoptosis stimulants; Mitogen-activated protein kinase modulators; Protein kinase C stimulants
Orphan Drug Status No
New Molecular Entity Yes
Available For Licensing Yes
Highest Development Phases

Phase II Acute myeloid leukaemia
Phase I/II Myelodysplastic syndromes
Preclinical Stroke
No development reported HIV infections
Most Recent Events

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up